Bris­tol My­ers pe­ti­tions the Supreme Court in a fi­nal bid to prove Gilead­'s Kite in­fringed on CAR-T patents

Five years af­ter Juno and Sloan Ket­ter­ing launched a bit­ter­ly fought le­gal cam­paign against Gilead’s Kite Phar­ma, claim­ing the biotech ri­val had in­fringed on its CAR-T patents on the way to launch­ing a pi­o­neer­ing can­cer ther­a­py, Bris­tol My­ers Squibb is tak­ing the case all the way to the Supreme Court.

The Juno ac­quir­er says that a Fed­er­al Cir­cuit de­ci­sion that set aside a $1.2 bil­lion ver­dict in its fa­vor was not just in­cor­rect, it has blight­ed the field of drug de­vel­op­ment and cre­at­ed a prece­dent that threat­ens the very foun­da­tion of in­no­va­tion in Amer­i­ca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER